SCHEMBL30765671

SCHEMBL30765671

COC(=O)c1ccc(-c2ccccc2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.55
SLC6A3 Q01959 4/20 0.51
SLC6A4 P31645 2/20 0.51
EGFR P00533 1/20 0.51
MAPT P10636 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
ABCB1 P08183 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
ABCC1 P33527 1/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
HNF4A P41235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651623 1.00 NR4A2 (0.55) NR4A2SLC6A3SLC6A4EGFRMAPT
SCHEMBL2941745 0.88 SLC6A3 (0.57) NR4A2SLC6A3SLC6A4MAPTCYP1A2
SCHEMBL9143243 0.87 CA12 (0.54) NR4A2SLC6A3SLC6A4ALDH1A1GAA
SCHEMBL22319386 0.87 NR4A2 (0.55) NR4A2SLC6A3SLC6A4EGFRMAPT
SCHEMBL38655411 0.85 GAA (0.54) NR4A2SLC6A3SLC6A4MAPTALDH1A1
SCHEMBL2296342 0.85 KDM4E (0.58) MAPTCYP1A2CYP2C19ABCB1ALDH1A1
SCHEMBL14252250 0.84 NR4A2 (0.59) NR4A2SLC6A3SLC6A4EGFRMAPT
SCHEMBL70440 0.84 NR4A2 (0.59) NR4A2SLC6A3SLC6A4EGFRMAPT
SCHEMBL16609019 0.83 LMNA (0.51) SLC6A3SLC6A4GAAKDM4ELMNA
SCHEMBL17996053 0.83 CFTR (0.47) SLC6A3SLC6A4EGFRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed